BioInvent Receives FDA Fast Track Designation for BI-1808
LUND, Sweden, August 7, 2026 BioInvent International AB announced that the U.S. Food and Drug Administration (FDA) has granted...
BI-1808
Advertisement
BioInvent’s TNFR2 Antibody BI-1808 Shows Promising Responses in Advanced CTCL at EHA 2026
LUND, Sweden, June 11, 2026 BioInvent International AB presented new clinical data from its ongoing Phase 2a study evaluating...
BioInvent to Showcase BI-1206 and BI-1808 Hematology Progress at June KOL Event
LUND, Sweden, June 1, 2026 BioInvent International AB announced that it will host a key opinion leader (KOL) event...
BioInvent Reports Strong BI-1808 CTCL Responses at EHA
LUND, Sweden – May 12, 2026 BioInvent International AB announced new Phase 2a clinical data demonstrating that its investigational...
EMA Positive Opinion Grants Orphan Drug Hope for CTCL Treatment
Dateline – November 17 2025 | Lund, Sweden BioInvent International AB (“BioInvent”), a clinical-stage biotech company focused on novel...
Advertisement
